{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:45:35Z","timestamp":1761101135361},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/cco.0000000000000010","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T22:38:16Z","timestamp":1380321496000},"page":"716-721","source":"Crossref","is-referenced-by-count":7,"title":["Recent advances in the management of mantle cell lymphoma"],"prefix":"10.1097","volume":"25","author":[{"given":"Noridza","family":"Rivera-Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cabanillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20-20210128","first-page":"3909","article-title":"The Non-Hodgkins Lymphoma Classification Project.","volume":"89","year":"1997","journal-title":"Blood"},{"key":"R2-20-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma.","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"R3-20-20210128","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma.","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"R4-20-20210128","first-page":"115","article-title":"Mantle-cell lymphoma.","volume":"36","author":"Campo","year":"1999","journal-title":"Semin Hematol"},{"key":"R5-20-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"R6-20-20210128","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","article-title":"Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkins lymphoma and mantle cell lymphoma.","volume":"23","author":"OConnor","year":"2005","journal-title":"J Clin Oncol"},{"key":"R7-20-20210128","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"R8-20-20210128","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"R9-20-20210128","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"R10-20-20210128","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.","volume":"27","author":"Damon","year":"2009","journal-title":"J Clin Oncol"},{"key":"R11-20-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi.","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"R12-20-20210128","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC autologous stem-cell support: still very long survival but late relapses do occur.","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"R13-20-20210128","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe dEtude des Lymphomes de lAdulte.","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"R14-20-20210128","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499.","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"R15-20-20210128","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study.","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"R16-20-20210128","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"R17-20-20210128","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial.","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"R18-20-20210128","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma.","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"R19-20-20210128","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/bjh.12008","article-title":"Single-agent lenalidomide in relapsedrefractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.","volume":"159","author":"Eve","year":"2012","journal-title":"Br J Haematol"},{"key":"R22-20-20210128","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3324\/haematol.2011.053173","article-title":"A multicenter phase II trial (SAKK 3606) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.","volume":"97","author":"Renner","year":"2012","journal-title":"Haematologica"},{"key":"R23-20-20210128","first-page":"55","article-title":"A phase ii multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsedrefractory follicular lymphoma (FL) and mantle cell lymphoma (MCL).","volume":"120","author":"Evens","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"key":"R24-20-20210128","doi-asserted-by":"crossref","first-page":"8519","DOI":"10.1200\/jco.2013.31.15_suppl.8519","article-title":"Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110 (PI3K), in patients with relapsed or refractory mantle cell lymphoma (MCL).","volume":"31","author":"Spurgeon","year":"2013","journal-title":"J Clin Oncol"},{"key":"R25-20-20210128","doi-asserted-by":"crossref","first-page":"8520","DOI":"10.1200\/jco.2013.31.15_suppl.8520","article-title":"Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsedrefractory non-Hodgkin lymphoma (NHL).","volume":"31","author":"Davids","year":"2013","journal-title":"J Clin Oncol"},{"key":"R26-20-20210128","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-20-20210128","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"R28-20-20210128","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkins lymphoma.","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"key":"R29-20-20210128","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkins Lymphoma.","volume":"27","author":"Witzig","year":"2009","journal-title":"J Clin Oncol"},{"key":"R30-20-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo.","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"key":"R31-20-20210128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals.","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"R33-20-20210128","first-page":"1433","article-title":"Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells.","volume":"90","author":"Hipp","year":"2005","journal-title":"Haematologica"},{"key":"R34-20-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-642-21631-2_2","article-title":"The biology of HDAC in cancer: the nuclear and epigenetic components.","volume":"206","author":"Hagelkruys","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"R35-20-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12094-010-0527-3","article-title":"Epigenetic therapy of lymphoma using histone deacetylase inhibitors.","volume":"12","author":"Cotto","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"R36-20-20210128","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkins lymphoma and mantle cell lymphoma.","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J Clin Oncol"},{"key":"R38-20-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation.","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"R39-20-20210128","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3KAkt signalling pathway and cancer.","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat Rev"},{"key":"R40-20-20210128","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"key":"R41-20-20210128","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"key":"R42-20-20210128","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"R43-20-20210128","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"R44-20-20210128","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/1042819031000151112","article-title":"Altered apoptosis pathways in mantle cell lymphoma.","volume":"45","author":"Rummel","year":"2004","journal-title":"Leuk Lymphoma"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T23:54:42Z","timestamp":1620950082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201311000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000010","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}